---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-031589"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T01:12:50.773542+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ImmuCell reports record Q1 2024 sales of $7.3M, up 111% YoY

## Summary
- Total sales for Q1 2024: $7.3M, 111% increase from $3.4M in Q1 2023.
- Trailing twelve-month sales ended Mar 31, 2024: $21.3M, up 33% from $16.0M.
- Backlog of orders $9.1M at Mar 31, 2024, down from $9.4M Dec 2023 but up from $2.5M Dec 2022.
- Company expects FDA response on Re-Tain CMC Technical Section by May 2024.

## SEC filing metadata
- accession: 0001213900-24-031589
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390024031589/0001213900-24-031589-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390024031589/ea0203580-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-031589
- JSON: https://secwatch.observer/filing/0001213900-24-031589.json
- Plain text: https://secwatch.observer/filing/0001213900-24-031589.txt

## Key facts
- Earnings Releases
  IMMUCELL CORP /DE/ reported Q1 2024 results: revenue $ 7.3 million.
  - Period: Q1 2024
  - Revenue: $ 7.3 million
  - Result: preliminary results
  source text: first quarter of 2024, which ended March 31, 2024. Preliminary, Unaudited Total Sales Results: 2024 2023 $ Increase % Increase During the Three-Month Periods Ended March 31, $ 7.3 million $ 3.4 million $ 3.8 million 111 % During the Twelve-Month Periods Ended March 31, $ 21.3 million $ 16.0 million $ 5.3 million 33 % Total sales during the three-month period ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390024031589/0001213900-24-031589-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.